Disease-specific assays

HealthLinx has entered into a collaboration with Bruker Daltonics, which will focus on technology transfer and cooperation between the two firms to develop disease-specific assays for use in in-vitro diagnostic (IVD) research and clinical trials using Bruker Daltonics' ClinProt platform technology for clinical proteomics.

The collaboration involves the on-going discovery of new biomarkers for predictive diagnostic applications using Bruker Daltonics' autoflex MALDI-TOF mass spectrometer in combination with proprietary ClinProt magnetic bead sample preparation, and ClinProTools software for advanced visualisation and bioinformatics. HealthLinx will apply this technology platform to develop and commercialise biomarker applications in women's health for both research and clinical diagnostics. It is envisaged that, following validation, Australian government Therapeutic Goods Administration (TGA) registration of the ClinProt platform as a diagnostic pathology device will be sought. TGA registration has effect in both Australia and New Zealand, and is valuable in Singapore and Europe.

The first IVD product to be developed under the collaboration will be an ovarian cancer test that will use four biomarkers found in the serum of women with ovarian cancer.